Human pd-l1 antibodies and methods of use therefor
AssigneeBoard of Regents, The University of Texas System
InventorsMichael A. CURRAN, Carlo TONIATTI, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Bianka PRINZ, Nadthakarn BOLAND
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
Claims63
An antibody or antibody fragment comprising clone-paired heavy and light CDR sequences from Tables 3 and 4, respectively.
A method of treating a subject having cancer comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
A hybridoma or engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
A vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
A method of detecting a PD-L1 expressing cell in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) detecting a PD-L1 expressing in said sample by binding of said antibody or antibody fragment to a cell in said sample.
A method of treating immune suppression in a tumor microenvironment comprising:
- delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
Dependencies are inferred from the claim text.